Abstract
REPORT HIGHLIGHTS
The global market for treatments for syndromes of dementia and movement
disorders was valued at $10.5 billion in 2011 and should reach $11.1 billion
in 2012. Total market value is expected to reach $16.7 billion in 2017 after
increasing at a five-year compound annual growth rate (CAGR) of 8.5%.
Treatments for movement disorders are expected to be worth $3.2 billion in
2012 and $4.8 billion in 2017, a CAGR of 8.3%.
Sales of Parkinson's drugs used to treat movement disorder syndromes are
expected to have a value of $2.9 billion in 2012 and nearly $4.3 billion in
2017, a CAGR of 8.1%
REPORT SCOPE
INTRODUCTION
STUDY OBJECTIVES
BCC's goal in conducting this study is to provide an overview of the current
and future characteristics of the global markets for treatments for syndromes
of dementia and movement disorders. The key objective is to present a
comprehensive analysis and the future direction of the market as it shapes
drug and therapy development.
This report explores present and future strategies within the
neurodegenerative disorder market, which includes treatments and therapies for
progressive dementia, progressive dementia with other neurological
abnormalities and movement disorders. Market gains, setbacks and needs are
discussed in this report. Comparisons, usage and the advantages and
disadvantages of different types of technologies, including small molecules
and monoclonal antibodies, are also presented in this report.
A detailed analysis of the structure of the syndromes of dementia and movement
disorder industry has been conducted. Revenues are broken down by
neurodegenerative disease and primary clinical/pathological feature. Sales
figures are estimated for the five-year period from 2012 through 2017.
Applications for syndromes of dementia and movement disorder treatments, or
therapeutic technologies, are also discussed separately in the report, with an
emphasis on small molecule and monoclonal antibodies technology. The report
also covers significant patents and their allotment in each category.
REASONS FOR DOING THIS STUDY
Extensive research in the field of syndromes of dementia and movement
disorders and company collaborations with research institutes have highlighted
the importance of understanding the nature of these disorders. New
technological developments are providing disease-modifying therapies for the
late stages of the disorders. Collaborations between research institutes and
pharmaceutical companies are on the rise as state-of-the-art technology is
being explored to develop more efficient products and therapies.
R&D spending, along with increasing competition, patent expiries and new
technologies are taking the market in a new direction. Global market revenues
increased from 2009 to 2011 and are expected to continue to show growth over
the forecast period as new advances, launches and collaborations continue to
influence the market. This study looks at most of the systems affected by
these factors.
Acquisition strategies and collaborations by companies are also covered in
this report. This study also discusses the strength and weaknesses of each
type of technology in light of the new technologies, growing competition and
changing customer needs.
CONTRIBUTIONS OF THE STUDY AND FOR WHOM
This study contributes to the areas of market growth in treatments for
Alzheimer's disease, Lewy body dementia, Pick's disease, Huntington's disease,
corticobasal ganglionic degeneration, Parkinson's disease, multiple system
atrophy, progressive supranuclear palsy and Hallervorden-Spatz disease.
Pharmaceutical biotechnical companies, research institutes and physicians will
find this study to be of interest.
SCOPE OF THE STUDY
The scope of this study encompasses the neurodegenerative disorders in the
pharmaceutical and biotechnology markets. BCC analyzes each market and its
applications, regulatory environment, technology involved, market projections
and market share. Technological issues include the latest trends and
developments. The emerging market for enzyme inhibitors includes countries
such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New
Zealand and Mexico.
METHODOLOGY
BCC conducted a comprehensive literature search, which included technical
newsletters and journals, and many other sources. Data were collected through
interviews and correspondence with manufacturers of enzyme inhibitors'
technical experts. Projections were based on estimates such as the current
number of end users, potential end users, mergers and acquisitions, and market
trends.
INFORMATION SOURCES
Many companies within the industry were surveyed to obtain data for this
study. Included were manufacturers and end users of enzyme inhibitors in
therapeutic categories and various disease sectors industries. Data were
gathered from various industry sources. BCC spoke with officials within the
industry, consulted newsletters, company literature, product literature and a
host of technical articles, journals, indexes and abstracts. Exhaustive
investigations of databases by key terminology were completed. In addition,
data were compiled from current financial, trade and government sources.
ABOUT THE AUTHOR
The study has been carried out by a team of professionals in the biotechnology
industry. The project manager for this study is Shalini S. Dewan, who holds a
master's degree in pharmaceutical chemistry and has more than 14 years of
industry experience. Among the research topics she has covered are studies on
compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl
acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India
for her work and has worked with top companies in India and in the U.S.
Some of her other reports with BCC include Reagents for Chromatography;
Spectroscopy - An Enduring Market; Advanced Drug Delivery Systems -
Technologies and Global Markets; Orthopedic Drugs, Implants and Devices -
Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory
Industry - The Dynamic Media, Sera and Reagent Market in Biotechnology;
Contract Pharmaceutical Manufacturing, Research and Packaging - Global
Markets; Chiral Technology - Global Markets; Autacoids and Related Drugs -
Technologies and Global Markets; Contraceptives - Technologies and Global
Markets; Liver Disease Treatments - The Global Market; Hormone Replacement
Therapies and Other Hormone Therapies - Global Markets; Cardiovascular
Medicine - Diagnostics, Drugs and Devices; and Cancer Therapies - Technologies
and Global Markets.
The lead consultant on this project is Ms. Ruma Chakravarty, who holds a
master's degree in biophysics. She has tremendous experience in market
research, quality, process improvement and lean and six sigma concepts.
Table of Contents
Chapter- 1: INTRODUCTION - Complimentary
- STUDY OBJECTIVES
- REASONS FOR DOING THIS STUDY
- CONTRIBUTIONS OF THE STUDY AND FOR WHOM
- SCOPE OF THE STUDY
- METHODOLOGY
- INFORMATION SOURCES
- ABOUT THE AUTHOR
- RELATED BCC RESEARCH REPORTS
- BCC ONLINE SERVICES
- DISCLAIMER
Chapter- 2: EXECUTIVE SUMMARY
- Table Summary : GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDERS, THROUGH 2017
- Figure Summary : GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS, 2010-2017
Chapter- 3: OVERVIEW
- THE BRAIN
- CLASSIFICATION OF NEURODEGENERATIVE DISORDERS
- NEURODEGENERATIVE DISORDERS
- DIAGNOSTIC TESTS FOR NEURODEGENERATIVE DISORDERS
Chapter- 4: REGULATORY ASPECTS
- INTRODUCTION
- DRUG APPROVALS
- REGULATORY DEVELOPMENTS AFFECTING SYNDROMES OF DEMENTIA AND MOVEMENT
DISORDER PRODUCTS
Chapter- 5: NEW DEVELOPMENTS
- Table 6 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS, 2012
- Table 7 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS, 2011
- Table 8 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS, 2010
Chapter- 6: GLOBAL MARKETS
- MARKETS BY CLINICAL/PATHOLOGICAL FEATURE
- MARKET BY DISEASE TYPE
- MARKET BY REGION
- MARKETS BY TECHNOLOGY
Chapter- 7: MARKET FOR MOVEMENT DISORDER SYNDROMES
- MARKET BY TYPE OF DISEASE
- MARKETS BY REGION
- REGIONAL MARKETS BY DISEASE TYPE
- MARKET BY TECHNOLOGY
- INDUSTRY STRUCTURE
Chapter- 8: PATENT ANALYSIS
- PATENTS ISSUED BY YEAR
- PATENTS BY DISEASE CATEGORY
- PATENTS BY DISEASE TYPE
- PATENTS BY COUNTRY
- PATENTS BY COMPANY
Chapter- 9: CURRENT SITUATION
- MARKET TRENDS
- OVERALL DRIVERS OF THE MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDERS
- OTHER FACTORS AFFECTING THE MARKET
- COLLABORATIONS/MERGERS AND ACQUISITIONS
Chapter- 10: COMPANY PROFILES
- ABBOTT LABORATORIES
- ABLYNX NV
- ACCERA INC.
- ACORDA THERAPEUTICS INC.
- ACTAVIS ELIZABETH
- AFFIRIS AG
- ALLIANCE PHARMA PLC
- ALLON THERAPEUTICS INC.
- ALPHAPHARM
- ALZHYME LTD.
- AMERICAN REGENT INC.
- APOTEX INC.
- APOTHECA INC.
- ASTELLAS PHARMA INC.
- ASTRAZENECA GMBH
- AUROBINDO PHARMA LTD.
- BAXTER INTERNATIONAL INC.
- BELLUS HEALTH INC.
- BOEHRINGER INGELHEIM LTD.
- BRISTOL-MYERS SQUIBB
- BRYANT RANCH PREPACK
- CADILA HEALTHCARE LTD.
- CARACO PHARMACEUTICAL LABORATORIES
- CARDINAL HEALTH
- CELLZOME AG
- CIPLA LTD.
- COGNITION THERAPEUTICS INC.
- COLUCID PHARMACEUTICALS INC.
- COMENTIS INC.
- CORTEX PHARMACEUTICALS
- CYTOS BIOTECHNOLOGY AG
- DAIICHI SANKYO CO. LTD.
- DR. REDDY'S LABORATORIES LTD.
- EISAI CO. LTD.
- ELAN PHARMA INTERNATIONAL LTD.
- ELI LILLY AND CO.
- ENDO PHARMACEUTICALS INC.
- ENVIVO PHARMACEUTICALS
- EVOTEC AG
- EPITOMICS INC.
- EXONHIT THERAPEUTICS SA
- FOREST LABORATORIES INC.
- GLAXOSMITHKLINE PLC
- GLENMARK GENERICS LTD.
- H. LUNDBECK A/S
- HAMELN PHARMACEUTICALS LTD.
- HELICON THERAPEUTICS INC.
- HOSPIRA INC.
- INTELLECT NEUROSCIENCES INC.
- INTRA-CELLULAR THERAPIES INC.
- JAZZ PHARMACEUTICALS PLC
- MAJOR PHARMACEUTICALS
- MEDIVATION INC.
- MEMORY PHARMACEUTICALS CORP.
- MERCK SERONO
- MERCK SHARP & DOHME LTD.
- MERZ PHARMA GMBH & CO KGAA
- MITHRIDION INC.
- MYLAN PHARMACEUTICALS
- NEUREN PHARMACEUTICALS LTD.
- NEURO-HITECH INC.
- NEUROPTIX CORP.
- NEUROSEARCH A/S
- NEWRON PHARMACEUTICALS SPA
- NOSCIRA SA
- NOVARTIS AG
- NYMOX PHARMACEUTICAL CORP.
- ORCHID CHEMICALS & PHARMACEUTICALS LTD.
- ORION CORP.
- ORTHO-MCNEIL JANSSEN PHARMACEUTICALS INC.
- PAR PHARMACEUTICALS
- PERRIGO CO.
- PFIZER INC.
- PHARNEXT
- PHYSICIANS TOTAL CARE INC.
- PLIVA HRVATSKA D.O.O.
- PRASCO LABORATORIES
- RANBAXY LABORATORIES LTD.
- ROCHE HOLDING LTD.
- ROXANE LABORATORIES INC.
- SANDOZ INTERNATIONAL GMBH
- SANOFI
- SANTHERA PHARMACEUTICALS
- SHIONOGI & CO.
- STADA ARZNEIMITTEL AG
- SUN PHARMA
- TAJ PHARMACEUTICALS LTD.
- TAKEDA PHARMACEUTICAL CO. LTD.
- TERCICA INC.
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
- TORRENT PHARMA
- UCB SA
- UDL LABORATORIES
- UPSHER-SMITH LABORATORIES
- VALEANT PHARMACEUTICALS
- VERNALIS PLC
- WATSON PHARMACEUTICALS INC.
- WEST-WARD PHARMACEUTICAL
Chapter- 11: APPENDIX I: ABBREVIATIONS
List of Tables
- Summary Table : GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDERS, THROUGH 2017
- Table 1 : CLASSIFICATION OF SYNDROMES OF DEMENTIA AND MOVEMENT DISORDERS
BY PRIMARY CLINICAL/PATHOLOGICAL FEATURE
- Table 2 : ANDA AND NDA APPROVALS OF DRUGS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS, 2010 TO MARCH 2012
- Table 3 : PENDING NEW DRUG APPLICATIONS FOR DRUGS USED TO TREAT SYNDROMES
OF DEMENTIA AND MOVEMENT DISORDERS
- Table 4 : FDA DRUG SAFETY ALERTS, 2010 TO MARCH 2012
- Table 5 : FDA RECALLS OF DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDERS, 2010 TO MARCH 2012
- Table 6 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS, 2012
- Table 7 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS, 2011
- Table 8 : NEW DEVELOPMENTS IN DRUGS USED TO TREAT SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS, 2010
- Table 9 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS, THROUGH 2017
- Table 10 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT
NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011
- Table 11 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJOR
NEURODEGENERATIVE DISORDERS, THROUGH 2017
- Table 12 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES
OF DEMENTIA AND MOVEMENT DISORDERS BY DISEASE TYPE, 2011
- Table 13 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS BY REGION, THROUGH 2017
- Table 14 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES
OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011
- Table 15 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, THROUGH 2017
- Table 16 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES
OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011
- Table 17 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER
SYNDROMES BY DISEASE TYPE, THROUGH 2017
- Table 18 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT
DISORDER SYNDROMES BY DISEASE TYPE, 2011
- Table 19 : GLOBAL SALES OF DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES
BY REGION, THROUGH 2017
- Table 20 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT
DISORDER SYNDROMES BY REGION, 2011
- Table 21 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PARKINSON'S DISEASE
BY REGION, THROUGH 2017
- Table 22 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MULTIPLE SYSTEM
ATROPHY BY REGION, THROUGH 2017
- Table 23 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE
SUPRANUCLEAR PALSY BY REGION, THROUGH 2017
- Table 24 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT HALLERVORDEN-SPATZ
DISEASE BY REGION, THROUGH 2017
- Table 25 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER
SYNDROMES BY TECHNOLOGY, THROUGH 2017
- Table 26 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT
DISORDER SYNDROMES BY TECHNOLOGY, 2011
- Table 27 : LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO
TREAT PARKINSON'S DISEASE
- Table 28 : MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO
TREAT PARKINSON'S DISEASE, 2011
- Table 29 : LEADING MANUFACTURERS/DISTRIBUTORS OF DRUGS/THERAPIES USED TO
TREAT MULTIPLE SYSTEM ATROPHY
- Table 30 : MANUFACTURERS/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED
TO TREAT MULTIPLE SYSTEM ATROPHY, 2011
- Table 31 : LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO
TREAT PROGRESSIVE SUPRANUCLEAR PALSY
- Table 32 : MANUFACTURERS/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED
TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY, 2011
- Table 33 : LEADING MANUFACTURERS/SUPPLIERS OF DRUGS/THERAPIES USED TO
TREAT HALLERVORDEN-SPATZ DISEASE
- Table 34 : MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED TO
TREAT HALLERVORDEN-SPATZ DISEASE, 2011
- Table 35 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDERS ISSUED PER YEAR, 2010 - MARCH 2012
- Table 36 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDERS BY CATEGORY OF DISEASE, 2010-MARCH 2012
- Table 37 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA
(PROGRESSIVE DEMENTIA) BY CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012
- Table 38 : U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES
BY DISEASE TYPE, 2010-MARCH 2012
- Table 39 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA
(PROGRESSIVE DEMENTIA) BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012
- Table 40 : U.S. PATENT SHARES OF DRUGS USED TO TREAT PROGRESSIVE DEMENTIA
BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012
- Table 41 : U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES
BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012
- Table 42 : U.S. PATENT SHARES OF DRUGS USED TO TREAT MOVEMENT DISORDER
SYNDROMES BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012
- Table 43 : NUMBER OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF
DEMENTIA (PROGRESSIVE DEMENTIA) BY COMPANY, 2010-MARCH 2012
- Table 44 : U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER SYNDROMES
BY COMPANY, 2010-MARCH 2012
List of Figures
- Summary Figure : GLOBAL MARKET FOR TREATMENTS FOR SYNDROMES OF DEMENTIA
AND MOVEMENT DISORDERS, 2010-2017
- Figure 1 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS, 2010-2017
- Figure 2 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT
NEURODEGENERATIVE DISORDERS BY CLINICAL/PATHOLOGICAL FEATURE, 2011
- Figure 3 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MAJOR
NEURODEGENERATIVE DISORDERS, 2010-2017
- Figure 4 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES
OF DEMENTIA AND MOVEMENT DISORDERS BY DISEASE, 2011
- Figure 5 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2010-2017
- Figure 6 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES
OF DEMENTIA AND MOVEMENT DISORDERS BY REGION, 2011
- Figure 7 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2010-2017
- Figure 8 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT SYNDROMES
OF DEMENTIA AND MOVEMENT DISORDERS BY TECHNOLOGY, 2011
- Figure 9 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER
SYNDROMES BY DISEASE TYPE, 2010-2017
- Figure 10 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT
DISORDER SYNDROMES BY DISEASE TYPE, 2011
- Figure 11 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER
SYNDROMES BY REGION, 2010-2017
- Figure 12 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT
DISORDER SYNDROMES BY REGION, 2011
- Figure 13 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PARKINSON'S
DISEASE BY REGION, 2010-2017
- Figure 14 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MULTIPLE SYSTEM
ATROPHY BY REGION, 2010-2017
- Figure 15 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT PROGRESSIVE
SUPRANUCLEAR PALSY BY REGION, 2010-2017
- Figure 16 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT HALLERVORDEN-SPATZ
DISEASE BY REGION, 2010-2017
- Figure 17 : GLOBAL SALES OF DRUG PRODUCTS USED TO TREAT MOVEMENT DISORDER
SYNDROMES BY TECHNOLOGY, 2010-2017
- Figure 18 : GLOBAL MARKET SHARES OF DRUG PRODUCTS USED TO TREAT MOVEMENT
DISORDER SYNDROMES BY TECHNOLOGY, 2011
- Figure 19 : MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED
TO TREAT PARKINSON'S DISEASE, 2011
- Figure 20 : MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED
TO TREAT MULTIPLE SYSTEM ATROPHY, 2011
- Figure 21 : MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED
TO TREAT PROGRESSIVE SUPRANUCLEAR PALSY, 2011
- Figure 22 : MANUFACTURER/DISTRIBUTOR MARKET SHARES OF DRUG PRODUCTS USED
TO TREAT HALLERVORDEN-SPATZ DISEASE, 2011
- Figure 23 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA AND
MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012
- Figure 24 : PERCENTAGE OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012
- Figure 25 : PERCENTAGE OF U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF
DEMENTIA AND MOVEMENT DISORDERS ISSUED PER YEAR, 2010-MARCH 2012
- Figure 26 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA BY
CLINICAL/PATHOLOGICAL FEATURE, 2010-MARCH 2012*
- Figure 27 : U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER
SYNDROMES BY DISEASE TYPE, 2010-MARCH 2012
- Figure 28 : U.S. PATENTS ON DRUGS USED TO TREAT SYNDROMES OF DEMENTIA
(PROGRESSIVE DEMENTIA) BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012
- Figure 29 : U.S. PATENTS ON DRUGS USED TO TREAT MOVEMENT DISORDER
SYNDROMES BY PATENT HOLDER'S COUNTRY, 2010-MARCH 2012
Global Markets for Treatments of Dementia and Movement Disorders -- Focus on Movement Disorders published by BCC Research in September 28, 2012. This report consists of 172 Pages and the price starts from US $ 4400.
